Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytodyne to appeal lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Xenadrine marketer will appeal class action ruling by San Diego state court May 30 that firm's ads for ephedra-containing Xenadrine RFA-1 are false, deceptive. Judge Ronald Styn ordered firm to pay $12.5 mil. to California consumers because it is "money obtained by means of unlawful practice." Ruling maintains Cytodyne's "before and after" testimonies are misleading, exaggerate individual results. In response, firm states "we believe California's false advertising laws are so lax that they literally permit any business that advertises a product to be sued - even when, as here, the plaintiff's lawyer doesn't have an injured or deceived client." Plaintiff's lawyer Todd Macaluso of San Diego-based Macaluso & Associates reportedly also will represent parents of Steve Bechler in suit against Cytodyne...
Advertisement

Related Content

Cytodyne Products’ Distribution And Sales Rights Licensed To Phoenix Labs

Topics

Advertisement
UsernamePublicRestriction

Register

PS095550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel